<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02637895</url>
  </required_header>
  <id_info>
    <org_study_id>20150534</org_study_id>
    <nct_id>NCT02637895</nct_id>
  </id_info>
  <brief_title>Vortioxetine for Posttraumatic Stress Disorder</brief_title>
  <official_title>Evaluation of the Efficacy of Vortioxetine for Posttraumatic Stress Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Miami</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Miami</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Post-traumatic stress disorder (PTSD) can result from having experienced or witnessed a&#xD;
      traumatic event. Patients with PTSD symptoms can sometimes experience symptom relief after&#xD;
      treatment with antidepressants; however, few patients experience complete symptom relief.&#xD;
      There is a need to develop new treatments for PTSD.&#xD;
&#xD;
      This study will evaluate if 12 weeks of using Vortioxetine relieves PTSD symptoms.&#xD;
      Vortioxetine has been approved for the treatment of depression; however, Vortioxetine has not&#xD;
      been approved by the Food and Drug Administration for the treatment of PTSD.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients included in the study will either take the study medication or will take a placebo,&#xD;
      a pill without the active medication. This will be determined by chance like a flip of a&#xD;
      coin.&#xD;
&#xD;
      Study procedures will include taking study medication and coming to regular in-clinic visits.&#xD;
      Depending on the study visit, study tests may include the following: medical evaluations,&#xD;
      physical exams, body measurements, vital signs, blood and urine tests, pregnancy tests,&#xD;
      genetic testing, heart function monitoring, clinical and psychiatric measures,&#xD;
      neuropsychological testing (for example, investigators will test how well you remember words&#xD;
      or how fast you perform a certain task), a function test (for example, investigators will&#xD;
      test how well you perform certain daily tasks), and a test to measure your startle response.&#xD;
      A startle response is an unexpected response by a sudden activity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2016</start_date>
  <completion_date type="Actual">February 6, 2020</completion_date>
  <primary_completion_date type="Actual">January 22, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change Clinician Administered PTSD Scale Score</measure>
    <time_frame>Baseline, Up to Week 12</time_frame>
    <description>Clinician-Administered PTSD Scale (CAPS-5) has a total score ranging from 0-80 with the higher score indicating greater degree of PTSD symptom severity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants That Achieve Treatment Response Via Clinician Administered PTSD Scale (CAPS)-5</measure>
    <time_frame>Week 12</time_frame>
    <description>Number of participants that achieve treatment response will be reported as those that has achieved a 30% improvement in their CAPS-5 total score from baseline. CAPS-5 has a total score ranging from 0-80 with the higher score indicating greater degree of PTSD symptom severity. Observed cases only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Depressive Symptoms in PTSD</measure>
    <time_frame>Baseline, Up to Week 12</time_frame>
    <description>Montgomery-Asberg Depression Rating Scale (MADRS) has a total score ranging from 0-60, with 0 meaning no depressive symptoms and 60 meaning severe depressive symptoms.(MADRS). From the total score 0-60, with 0 meaning no depressive symptoms and 60 meaning severe depressive symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants That Achieve Treatment Response Via CGI-I</measure>
    <time_frame>Week 12</time_frame>
    <description>Clinical Global Impression of Improvement (CGI-I) is a 7 point Likert-scale questionnaire assessing PTSD symptoms improvement. A score of 1 indicates very much improved, 4 indicates no change and 7 indicates much worse. Treatment response will be reported as the number of participants with an improvement of 1-2 points on their CGI-I score from baseline. Analysis includes observed cases only.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Post-Traumatic Stress Disorder</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo pill once daily for 12 weeks of active treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vortioxetine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vortioxetine pill 10mg once daily up to 4 weeks followed by 20mg once daily if tolerated for the rest of the study. Patients unable to tolerate the 20 mg/day dose may be reduced to 10 mg/day between weeks 4 and 8. The dose of study medication should remain stable for weeks 8-12.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo pill matching Vortioxetine.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vortioxetine</intervention_name>
    <description>Immediate Release 10 mg. Vortioxetine Pill</description>
    <arm_group_label>Vortioxetine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion&#xD;
&#xD;
          1. Males and Females between the ages of 18 and 65&#xD;
&#xD;
          2. Fulfills Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5)&#xD;
             criteria for primary diagnosis of PTSD.&#xD;
&#xD;
          3. Able to give consent&#xD;
&#xD;
          4. Willingness to sign the treatment contract&#xD;
&#xD;
          5. A negative urine toxicology&#xD;
&#xD;
          6. For females of reproductive age, use of an effective birth control method* for the&#xD;
             duration of the study or abstinence.&#xD;
&#xD;
          7. Duration of illness of PTSD for at least 3 months&#xD;
&#xD;
          8. An initial score at Screening, and Visit 3 (randomization) of â‰¥ 50 on the Clinician&#xD;
             Administered PTSD Scale (CAPS) for PTSD Studies&#xD;
&#xD;
        Exclusion&#xD;
&#xD;
          1. Lifetime or current diagnosis of schizophrenia or other psychotic disorder, dementia,&#xD;
             bipolar disorder.&#xD;
&#xD;
          2. Subject is currently participating in another clinical trial in which s/he is or will&#xD;
             be exposed to an investigational or non-investigational drug or device, or has done so&#xD;
             within the preceding month.&#xD;
&#xD;
          3. Current evidence or history of significant unstable medical illness or organic brain&#xD;
             impairment, including stroke, Central Nervous System (CNS) tumor, demyelinating&#xD;
             disease, cardiac, pulmonary, gastrointestinal, renal or hepatic impairment that would&#xD;
             likely interfere with the action, absorption, distribution, metabolism, or excretion&#xD;
             of Vortioxetine. History of moderate or more severe Traumatic Brain Injury (TBI) will&#xD;
             also be exclusionary.&#xD;
&#xD;
          4. Patients who in the investigator's judgment pose a current suicidal or homicidal risk&#xD;
&#xD;
          5. DSM-5 substance abuse or dependence within the past 90 days. Subject has a positive&#xD;
             urine toxicology test for illegal substances.&#xD;
&#xD;
          6. Diagnosis of anorexia nervosa, bulimia, or Obsessive Compulsive Disorder (OCD) in the&#xD;
             past year.&#xD;
&#xD;
          7. Subject has a documented history of hepato-biliary disease including a history of, or&#xD;
             positive laboratory results for hepatitis (hepatitis B surface antigen and/or&#xD;
             hepatitis C antibody), and clinically significant hepatic enzyme elevation, including&#xD;
             any one of the following enzymes greater than 3 times the upper limit of normal (ULN)&#xD;
             value (Alanine transaminase (ALT), aspartate aminotransferase (AST), alkaline&#xD;
             phosphatase( ALP)), or total or direct bilirubin &gt; 1.5 x ULN, unless consistent with&#xD;
             presumed or diagnosed Gilbert's disease&#xD;
&#xD;
          8. Subject has taken systemic corticosteroids within 2 weeks of the Randomization Visit&#xD;
&#xD;
          9. Treatment with any other psychoactive medication within 2 weeks of Visit 1, including&#xD;
             all antidepressants, psychoactive herbal or nutritional treatment (St Johns&#xD;
             Wort,S-Adenosyl methionine(SAM-e)), lithium, other mood stabilizers, oral&#xD;
             antipsychotics, depot antipsychotics within 12 weeks, beta blockers, thioridazine,&#xD;
             pimozide, opiates, anxiolytics, and sedatives (with the exception of zolpidem,&#xD;
             eszopiclone, and zaleplon). Also any treatment with any medication that the PI judges&#xD;
             not acceptable for this study.&#xD;
&#xD;
         10. Pregnancy or lactation*&#xD;
&#xD;
         11. Subjects who, in the opinion of the investigator, would be noncompliant with the visit&#xD;
             schedule or study procedures (e.g. illiteracy, planned vacations, or planned&#xD;
             hospitalizations during the study).&#xD;
&#xD;
         12. Any laboratory abnormality that in the investigator's judgment is considered to be&#xD;
             clinically significant&#xD;
&#xD;
         13. Patients who are receiving exposure-based psychotherapy that targets PTSD symptoms&#xD;
&#xD;
         14. Current or planned litigation or other actions related to secondary gain regarding the&#xD;
             traumatic event&#xD;
&#xD;
         15. Subject has clinical evidence of, or ElectroCardiogram (ECG) results indicating any of&#xD;
             the following at either screen or Randomization Visit unless repeat ECG shows that the&#xD;
             parameter had returned to within normal range by the Randomization Visit:&#xD;
&#xD;
               -  Q to T interval change (QTc)&gt; 450 msec for men, or &gt; 475 msec for women;&#xD;
&#xD;
               -  any cardiac condition or ECG evidence that the investigator feels may pose a&#xD;
                  potential safety concern.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philip Harvey, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Miami</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>December 15, 2015</study_first_submitted>
  <study_first_submitted_qc>December 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 22, 2015</study_first_posted>
  <results_first_submitted>November 30, 2020</results_first_submitted>
  <results_first_submitted_qc>January 19, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">February 8, 2021</results_first_posted>
  <last_update_submitted>January 19, 2021</last_update_submitted>
  <last_update_submitted_qc>January 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Miami</investigator_affiliation>
    <investigator_full_name>Philip D. Harvey</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>PTSD,</keyword>
  <keyword>trauma</keyword>
  <keyword>stress disorder</keyword>
  <keyword>post-traumatic stress disorder</keyword>
  <keyword>anxiety disorder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Stress Disorders, Traumatic</mesh_term>
    <mesh_term>Stress Disorders, Post-Traumatic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vortioxetine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 22, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/95/NCT02637895/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Placebo pill once daily for 12 weeks of active treatment.&#xD;
Placebo: Placebo pill matching Vortioxetine.</description>
        </group>
        <group group_id="P2">
          <title>Vortioxetine</title>
          <description>Vortioxetine pill 10mg once daily up to 4 weeks followed by 20mg once daily if tolerated for the rest of the study. Patients unable to tolerate the 20 mg/day dose may be reduced to 10 mg/day between weeks 4 and 8. The dose of study medication should remain stable for weeks 8-12.&#xD;
Vortioxetine: Vortioxetine pill 10mg once daily up to 4 weeks followed by 20mg once daily if tolerated for the rest of the study. Patients unable to tolerate the 20 mg/day dose may be reduced to 10 mg/day between weeks 4 and 8. The dose of study medication should remain stable for weeks 8-12.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Abnormal baseline lab</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Placebo pill once daily for 12 weeks of active treatment.&#xD;
Placebo: Placebo pill matching Vortioxetine.</description>
        </group>
        <group group_id="B2">
          <title>Vortioxetine</title>
          <description>Vortioxetine pill 10mg once daily up to 4 weeks followed by 20mg once daily if tolerated for the rest of the study. Patients unable to tolerate the 20 mg/day dose may be reduced to 10 mg/day between weeks 4 and 8. The dose of study medication should remain stable for weeks 8-12.&#xD;
Vortioxetine: Vortioxetine pill 10mg once daily up to 4 weeks followed by 20mg once daily if tolerated for the rest of the study. Patients unable to tolerate the 20 mg/day dose may be reduced to 10 mg/day between weeks 4 and 8. The dose of study medication should remain stable for weeks 8-12.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="21"/>
            <count group_id="B2" value="20"/>
            <count group_id="B3" value="41"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40.1" spread="11.0"/>
                    <measurement group_id="B2" value="44.3" spread="11.9"/>
                    <measurement group_id="B3" value="42.2" spread="11.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change Clinician Administered PTSD Scale Score</title>
        <description>Clinician-Administered PTSD Scale (CAPS-5) has a total score ranging from 0-80 with the higher score indicating greater degree of PTSD symptom severity.</description>
        <time_frame>Baseline, Up to Week 12</time_frame>
        <population>Mixed Model Repeated Measures (MMRM) Analysis of all Intent To Treat (ITT) cases</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo pill once daily for 12 weeks of active treatment.&#xD;
Placebo: Placebo pill matching Vortioxetine.</description>
          </group>
          <group group_id="O2">
            <title>Vortioxetine</title>
            <description>Vortioxetine pill 10mg once daily up to 4 weeks followed by 20mg once daily if tolerated for the rest of the study. Patients unable to tolerate the 20 mg/day dose may be reduced to 10 mg/day between weeks 4 and 8. The dose of study medication should remain stable for weeks 8-12.&#xD;
Vortioxetine: Vortioxetine pill 10mg once daily up to 4 weeks followed by 20mg once daily if tolerated for the rest of the study. Patients unable to tolerate the 20 mg/day dose may be reduced to 10 mg/day between weeks 4 and 8. The dose of study medication should remain stable for weeks 8-12.</description>
          </group>
        </group_list>
        <measure>
          <title>Change Clinician Administered PTSD Scale Score</title>
          <description>Clinician-Administered PTSD Scale (CAPS-5) has a total score ranging from 0-80 with the higher score indicating greater degree of PTSD symptom severity.</description>
          <population>Mixed Model Repeated Measures (MMRM) Analysis of all Intent To Treat (ITT) cases</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16" spread="3.00"/>
                    <measurement group_id="O2" value="17" spread="2.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants That Achieve Treatment Response Via Clinician Administered PTSD Scale (CAPS)-5</title>
        <description>Number of participants that achieve treatment response will be reported as those that has achieved a 30% improvement in their CAPS-5 total score from baseline. CAPS-5 has a total score ranging from 0-80 with the higher score indicating greater degree of PTSD symptom severity. Observed cases only.</description>
        <time_frame>Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo pill once daily for 12 weeks of active treatment.&#xD;
Placebo: Placebo pill matching Vortioxetine.</description>
          </group>
          <group group_id="O2">
            <title>Vortioxetine</title>
            <description>Vortioxetine pill 10mg once daily up to 4 weeks followed by 20mg once daily if tolerated for the rest of the study. Patients unable to tolerate the 20 mg/day dose may be reduced to 10 mg/day between weeks 4 and 8. The dose of study medication should remain stable for weeks 8-12.&#xD;
Vortioxetine: Vortioxetine pill 10mg once daily up to 4 weeks followed by 20mg once daily if tolerated for the rest of the study. Patients unable to tolerate the 20 mg/day dose may be reduced to 10 mg/day between weeks 4 and 8. The dose of study medication should remain stable for weeks 8-12.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants That Achieve Treatment Response Via Clinician Administered PTSD Scale (CAPS)-5</title>
          <description>Number of participants that achieve treatment response will be reported as those that has achieved a 30% improvement in their CAPS-5 total score from baseline. CAPS-5 has a total score ranging from 0-80 with the higher score indicating greater degree of PTSD symptom severity. Observed cases only.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Depressive Symptoms in PTSD</title>
        <description>Montgomery-Asberg Depression Rating Scale (MADRS) has a total score ranging from 0-60, with 0 meaning no depressive symptoms and 60 meaning severe depressive symptoms.(MADRS). From the total score 0-60, with 0 meaning no depressive symptoms and 60 meaning severe depressive symptoms.</description>
        <time_frame>Baseline, Up to Week 12</time_frame>
        <population>Mixed Model Repeated Measures (MMRM) Analysis of all Intent To Treat (ITT) cases</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo pill once daily for 12 weeks of active treatment.&#xD;
Placebo: Placebo pill matching Vortioxetine.</description>
          </group>
          <group group_id="O2">
            <title>Vortioxetine</title>
            <description>Vortioxetine pill 10mg once daily up to 4 weeks followed by 20mg once daily if tolerated for the rest of the study. Patients unable to tolerate the 20 mg/day dose may be reduced to 10 mg/day between weeks 4 and 8. The dose of study medication should remain stable for weeks 8-12.&#xD;
Vortioxetine: Immediate Release 10 mg. Vortioxetine Pill</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Depressive Symptoms in PTSD</title>
          <description>Montgomery-Asberg Depression Rating Scale (MADRS) has a total score ranging from 0-60, with 0 meaning no depressive symptoms and 60 meaning severe depressive symptoms.(MADRS). From the total score 0-60, with 0 meaning no depressive symptoms and 60 meaning severe depressive symptoms.</description>
          <population>Mixed Model Repeated Measures (MMRM) Analysis of all Intent To Treat (ITT) cases</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.73" spread="1.95"/>
                    <measurement group_id="O2" value="12.06" spread="2.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants That Achieve Treatment Response Via CGI-I</title>
        <description>Clinical Global Impression of Improvement (CGI-I) is a 7 point Likert-scale questionnaire assessing PTSD symptoms improvement. A score of 1 indicates very much improved, 4 indicates no change and 7 indicates much worse. Treatment response will be reported as the number of participants with an improvement of 1-2 points on their CGI-I score from baseline. Analysis includes observed cases only.</description>
        <time_frame>Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo pill once daily for 12 weeks of active treatment.&#xD;
Placebo: Placebo pill matching Vortioxetine.</description>
          </group>
          <group group_id="O2">
            <title>Vortioxetine</title>
            <description>Vortioxetine pill 10mg once daily up to 4 weeks followed by 20mg once daily if tolerated for the rest of the study. Patients unable to tolerate the 20 mg/day dose may be reduced to 10 mg/day between weeks 4 and 8. The dose of study medication should remain stable for weeks 8-12.&#xD;
Vortioxetine: Vortioxetine pill 10mg once daily up to 4 weeks followed by 20mg once daily if tolerated for the rest of the study. Patients unable to tolerate the 20 mg/day dose may be reduced to 10 mg/day between weeks 4 and 8. The dose of study medication should remain stable for weeks 8-12.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants That Achieve Treatment Response Via CGI-I</title>
          <description>Clinical Global Impression of Improvement (CGI-I) is a 7 point Likert-scale questionnaire assessing PTSD symptoms improvement. A score of 1 indicates very much improved, 4 indicates no change and 7 indicates much worse. Treatment response will be reported as the number of participants with an improvement of 1-2 points on their CGI-I score from baseline. Analysis includes observed cases only.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>16 weeks</time_frame>
      <desc>Only treatment-related adverse events, as evaluated by treating physician, will be reported at the 5% reporting threshold.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo pill once daily for 12 weeks of active treatment.&#xD;
Placebo: Placebo pill matching Vortioxetine.</description>
        </group>
        <group group_id="E2">
          <title>Vortioxetine</title>
          <description>Vortioxetine pill 10mg once daily up to 4 weeks followed by 20mg once daily if tolerated for the rest of the study. Patients unable to tolerate the 20 mg/day dose may be reduced to 10 mg/day between weeks 4 and 8. The dose of study medication should remain stable for weeks 8-12.&#xD;
Vortioxetine: Vortioxetine pill 10mg once daily up to 4 weeks followed by 20mg once daily if tolerated for the rest of the study. Patients unable to tolerate the 20 mg/day dose may be reduced to 10 mg/day between weeks 4 and 8. The dose of study medication should remain stable for weeks 8-12.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="10" subjects_affected="4" subjects_at_risk="21"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="21"/>
                <counts group_id="E2" events="16" subjects_affected="10" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="11" subjects_affected="4" subjects_at_risk="21"/>
                <counts group_id="E2" events="10" subjects_affected="6" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Philip Harvey</name_or_title>
      <organization>University of Miami Miller School of Medicine</organization>
      <phone>305 243 4094</phone>
      <email>pharvey@med.miami.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

